FIGURE 4.

CXCR5 mediates the VCAM‐1 expression and cell migration in response to CXCL13 incubation. A, The CL1‐0 lung cancer cells were transfected with CXCR5 siRNA for 24 h, and the knockdown efficiency of CXCR5 was confirmed by Western blot. B and C, The CL1‐0 lung cancer cells transfected with CXCR5 siRNA were further performed with cell migration assay B, in the presence of CXCL13 (30 ng/mL) for 24 h, as well as qPCR C, to detect VCAM‐1 expression. D and E, The CL1‐0 lung cancer cells were pre‐incubated with CXCR5 neutralized antibody (0.5 and 1 μg/mL) for 1 h and then performed with cell migration assay D, and qPCR E, in the presence of CXCL13 (30 ng/mL) for 24 h to evaluate cell migratory ability and VCAM‐1 expression, respectively. Results are expressed as the mean ± SD of triplicate samples. *P < .05 compared to the control group. #P < .05 compared to the CXCL13‐treated group